Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - 24/7 Wall St. Russell 20002,502.44 +0.30% FTSE 1009,953.60 -0.04% Nikkei 22552,743.00 -1.01% Stock Market Live March 24, 2026: S&P 500 (SPY) Under Pressure Again Investing S&P 5006,579.90 -0.18% Dow Jones46,338.00 +0.13% Nasdaq 10024,091.00 -0.55% Pfizer Could Hit $36 by Year-End as Analysts See 2- to-1 Payoff on Key Prostate Cancer Trial By Joel SouthPublished Mar 24, 10:52AM EDT Quick Read Pfizer (PFE) is trading ...

Fourth Quarter and Full Year 2025 Financial Results March 16, 2026 Forward-Looking Statements This presentation contains forward-looking statements regarding Kyntra Bio's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and pr ...

Core Insights - PROCEPT BioRobotics is shifting its sales strategy by eliminating end-of-quarter volume discounts to stabilize revenue and improve average selling prices (ASPs) [1][6][8] - The company has treated over 125,000 patients globally and has more than 900 instruments installed, marking a significant milestone with the transition to Category I reimbursement [2][4] - The market for benign prostatic hyperplasia (BPH) presents a large opportunity, with current Aquablation penetration at about 10% of the 400,000 annual prostate procedures [3][4] Financial Targets - For 2026, PROCEPT expects revenue between $390 million and $410 million, representing a growth of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65% [7][26] - The adjusted EBITDA loss is projected to be between $30 million and $17 million, with expectations of positive EBITDA in Q4 2026 [7][26] - The company anticipates over 25% revenue growth in 2027, aiming for a business exceeding $500 million and positive adjusted EBITDA of $25 million to $30 million [7][26] Product and Market Strategy - PROCEPT is pursuing a whole-gland prostate cancer strategy with the pivotal WATER IV trial, which is expected to complete procedures by mid-year and present results at AUA in 2027 [5][19] - The company is focusing on improving handpiece ASP to approximately $3,500 by 2026, which is a $300 increase from historical levels, and aims for a one-to-one alignment of handpiece sales to procedures [9][8] - A commercial reorganization has been implemented to enhance execution by integrating clinical and sales support under a single leadership structure [10][12] Marketing and Patient Engagement - The marketing strategy emphasizes increasing patient awareness and share capture, with current unaided awareness of Aquablation at only 1% to 2% [14][15] - Targeted digital engagement strategies are being developed for medically managed patients, focusing on those who are on BPH medications and have high discontinuation rates [15][16] Operational Improvements - The company has made operational changes to reduce time from purchase order to the completion of initial cases, achieving a 50% reduction in ramp-up time at new sites [12] - PROCEPT plans to offer trade-in credits for older systems to encourage replacements and is exploring leasing pilot programs, although leasing is not expected to be a major part of 2026 [13]

PROCEPT BioRobotics 2026 Investor Day Summary Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically focused on urology and BPH (Benign Prostatic Hyperplasia) treatment Key Points and Arguments Market Opportunity - Approximately **400,000 patients** undergo prostate procedures annually, with only **10% market penetration** by PROCEPT, indicating significant growth potential [2][3] - There are **8 million men** seeking therapy for BPH, many dissatisfied with current drug treatments [2] - Over **1 million men** discontinue medication annually due to ineffectiveness or side effects, presenting an additional opportunity [3] Technology and Clinical Evidence - PROCEPT has developed a **game-changing technology** for BPH treatment, with over **125,000 patients** treated and **900 instruments** installed globally [4][5] - The company emphasizes the importance of clinical evidence and aims to demonstrate effective execution in the field to drive market share [4] Reimbursement and Pricing Strategy - Transitioned to **Category I reimbursement** on January 1, 2026, which enhances the narrative around reimbursement and reduces previous uncertainties [5] - Handpiece pricing has seen a **$300 increase**, with expectations for **average selling price (ASP)** to reach **$3,500** in 2026 [11] Revenue Management - Eliminated end-of-quarter volume discounts to stabilize revenue and improve ASP, leading to more predictable ordering patterns [8][9] - Anticipates a **1-to-1 ratio** of handpiece sales to procedures, which is a conservative estimate given the addition of **200+ systems** in 2026 [13][14] Sales Organization Changes - Integrated clinical and sales support teams under a single regional leader to optimize resource allocation and improve performance [15][17] - Aimed to reduce the time from purchase order to first procedures by **50%** through better coordination [21] Strategic Focus Areas 1. **Accelerating Procedure Growth**: Targeting the **10% penetration** in the surgical market and increasing awareness of Aquablation therapy [54][56] 2. **Path to Profitability**: Emphasizing the need for a clear path to profitability and improved margins [4][10] 3. **Advancing Evidence and Innovation**: Continuing to invest in clinical evidence and exploring new indications, including prostate cancer treatment [45][46] Patient-Centric Approach - Highlighting the importance of preserving **urinary and sexual function** while providing effective symptom relief [34][42] - Addressing the misalignment between physician assumptions and patient desires regarding BPH treatment [63][64] - Developing targeted patient education initiatives to increase awareness and understanding of Aquablation therapy [68] Competitive Landscape - Positioning Aquablation as a superior alternative to traditional TURP procedures, which have been around for over **100 years** [31] - Emphasizing the unique benefits of Aquablation, including reduced complications and better long-term outcomes compared to other therapies [30][43] Future Growth Opportunities - Exploring leasing pilot programs to attract customers hesitant about capital expenditures [29] - Anticipating significant growth in the prostate cancer treatment market, leveraging existing technology and expertise [45][49] Additional Important Insights - The company is committed to educating both patients and clinicians about the benefits of Aquablation, aiming to shift perceptions and increase adoption [56][67] - The focus on **durability** and **long-term outcomes** is critical, as many contemporary BPH therapies struggle to maintain market momentum due to lack of sustained effectiveness [62] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics 2026 Investor Day, highlighting the company's growth potential, innovative technology, and commitment to patient-centered care.

Welcome to 2026 Analyst Day Matt Bacso VP, Investor Relations © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 1 This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. Exchange Commission ("SEC"), including the Ann ...

Core Insights - The AMPLITUDE clinical trial is the first to evaluate therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and known homologous recombination repair (HRR) gene alterations, showing positive results for the niraparib-based combination regimen as a potential new standard of care for patients with BRCA mutations [1][2] - The combination of niraparib and abiraterone acetate demonstrated a significant delay in disease progression and an early trend toward improved overall survival compared to standard care in mHSPC treatment [1][2] Group 1: Clinical Trial Results - The Phase 3 AMPLITUDE study involved 696 patients with mHSPC and HRR gene alterations, showing significant improvements in radiographic progression-free survival (rPFS) with the niraparib/AAP combination [2][3] - Patients with BRCA1/2 mutations experienced the most benefit, with a median rPFS not reached compared to 26 months for placebo plus AAP, reducing the risk of radiographic progression or death by 48% (HR 0.52, p<0.0001) [2][3] - The treatment also prolonged time to symptomatic progression by 56% in patients with BRCA alterations (HR 0.44, p=0.0001) [2][3] Group 2: Safety Profile - The safety profile of the niraparib/AAP combination was consistent with that observed in metastatic castration-resistant prostate cancer (mCRPC), with common Grade 3/4 adverse events being anemia and hypertension [2][4] - Treatment discontinuations due to adverse events remained low, and adverse events were manageable with dose modifications and supportive care [2][4] Group 3: Regulatory Developments - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended an indication extension for AKEEGA® (niraparib and abiraterone acetate) in combination with androgen deprivation therapy for patients with BRCA1/2 mutations [1][2] - This recommendation is based on the positive results from the AMPLITUDE study, highlighting the urgent medical need for targeted treatment strategies in high-risk populations [2][3] Group 4: Company Commitment - Johnson & Johnson emphasizes its commitment to personalized treatment approaches in prostate cancer, integrating targeted precision medicine into routine care [2][3] - The company aims to address the specific drivers of high-risk disease, reinforcing its legacy in prostate cancer treatment [2][3]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Summary of EDAP Conference Call Company Overview - **Company**: EDAP - **Industry**: MedTech, specifically focused on prostate cancer treatment through Focal therapy Key Points Capital Environment - The capital demand and spending environment for hospitals is under pressure, leading to strategic investments in clinically necessary equipment like Focal One, which addresses prostate cancer, the most diagnosed cancer in men [4][5] - EDAP reported a **167% growth** in capital sales for Focal One last quarter, indicating strong momentum in the capital equipment space [5] Market Dynamics - The U.S. market is characterized by a strategic approach to capital investments, while the international (OUS) market varies by region, with notable sales increases in Western Europe [6][7] - Focal therapy is emerging as the fastest-growing treatment category for prostate cancer, with hospitals increasingly recognizing its clinical value [6][7] Sales Process and Customer Engagement - The sales process is heavily influenced by clinical efficacy and economic arguments, with hospitals showing a preference for outpatient procedures that are economically viable [9][10] - EDAP is present in nearly **50 academic centers** in the U.S., including top institutions like Memorial Sloan Kettering and Mayo Clinic, with some hospitals acquiring multiple Focal One systems [10] Clinical Evidence and Adoption - The HIFI Study, involving **3,200 patients**, supports the efficacy of Focal therapy, showing oncologic control and better patient outcomes compared to radical treatments [17][21] - EDAP is in the early adopter phase of the market adoption lifecycle, with ongoing efforts to educate hospitals on the value of Focal therapy [18][19] Financial Performance - EDAP expects HIFU revenue to grow by **26-34%**, while non-core business is projected to decline by **25-30%** [46] - Gross margins for HIFU are trending in the high forties, with an increase from **39% to 42%** in Q3 2024, indicating a positive financial trajectory [47] Product Development and Future Outlook - The launch of Focal One Eye, a new platform, is expected to enhance performance and gross margins, with an average selling price of around **$650,000** in the U.S. [49] - EDAP is actively pursuing additional indications for HIFU technology, including studies for benign prostatic hyperplasia (BPH) and women's health applications [34][42][28] Strategic Focus - The company is transitioning away from non-core businesses to concentrate on HIFU, which is seen as the growth engine for the future [46][51] - EDAP is working with strategic suppliers to improve cost structures and optimize margins, aiming for mid-single-digit improvements in gross margins [54] Additional Insights - The company is leveraging its legacy in urology to expand its market presence and capitalize on the growing demand for targeted robotic HIFU therapy [22][23] - The potential for HIFU technology extends beyond prostate cancer, with applications being explored in various medical fields, indicating a broad growth opportunity [25][28]

Summary of ORIC Pharmaceuticals Conference Call Company Overview - **Company Name**: ORIC Pharmaceuticals - **Ticker**: NasdaqGS:ORIC - **Focus**: Development of small molecule drugs in oncology, specifically targeting solid tumors like prostate cancer and lung cancer [2][3] Key Points and Arguments Lead Programs - ORIC is currently focused on two lead programs in prostate cancer and lung cancer, both in dose optimization and expected to start pivotal phase three studies in 2026 [2][3] ORIC-944 Program - Recent data showed encouraging results for the ORIC-944 program, particularly in combination with apalutamide and daralutamide, with impressive PSA response rates [3][4] - ORIC-944 has a 20-hour half-life compared to Pfizer's memoremedistat, which has a five-hour half-life, suggesting a potential safety advantage [3][19] - The ability to clear ctDNA was observed in 59% of patients, which correlates strongly with long-term outcomes like PFS and OS [5][9] Safety Profile - The safety profile of ORIC-944 appears favorable, with only one grade 3 adverse event reported in 20 patients, compared to multiple grade 3 events in Pfizer's studies [13][15] - A clean safety profile is crucial for future development, especially in earlier lines of treatment for prostate cancer [14][15] Market Opportunity - The metastatic CRPC market is estimated at approximately 50,000 patients, with a total addressable market (TAM) of about $3.5 billion in the US for each of the post-AR inhibitors and post-abiraterone populations [29][30] - Historical data suggests that even with an undifferentiated profile, a second-to-market drug can capture about 35% of the market [30] Future Development Plans - ORIC plans to submit dose optimization data to regulators in early 2026 to align on pivotal study design [25][26] - The first phase three study is expected to start in the first half of 2026, with primary readout anticipated in the second half of 2027 [27][28] Pipeline Asset ORIC-114 - ORIC-114 is focused on non-small cell lung cancer, with updates expected at ESMO Asia in December, including data from multiple cohorts [35] - The drug is designed to be CNS-penetrant, which may lead to longer PFS outcomes for patients with brain metastases [36][37] Financial Position - As of the third quarter, ORIC had $413 million in cash and investments, providing a runway into the second half of 2028, covering pivotal studies for both ORIC-944 and ORIC-114 [42] Additional Important Information - ORIC maintains strong relationships with Bayer and Johnson & Johnson, which are crucial for future collaborations [31][32] - The company is exploring the potential of PRC2 inhibitors in other oncology indications beyond prostate cancer, including breast cancer and lung cancer [33][34]

Core Insights - ORIC Pharmaceuticals announced additional efficacy and safety data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC) [1][2] Efficacy Data - The trial demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate among patients [6] - Rapid and deep circulating tumor DNA (ctDNA) reductions were observed in 76% of patients, with 59% achieving ctDNA clearance, indicating potential long-term treatment benefits [1][7] - PSA responses and ctDNA reductions were consistent across all ORIC-944 dose levels and in combination with both apalutamide and darolutamide [4][5] Safety Profile - The combination of ORIC-944 with apalutamide or darolutamide showed a safety profile compatible with long-term dosing, with most adverse events being Grade 1 or 2 [8] - As of the cutoff date, only one patient experienced a Grade 3 treatment-related adverse event, with no Grade 4 or 5 adverse events reported [8] Next Steps - ORIC has selected provisional recommended Phase 2 doses for ORIC-944 to be tested in combination with darolutamide and apalutamide, with ongoing enrollment in the dose optimization portion of the trial [9] - Preliminary dose optimization data is expected to be announced in Q1 2026, ahead of initiating the first global Phase 3 registrational trial in mCRPC in the first half of 2026 [2][9] Company Overview - ORIC Pharmaceuticals is focused on developing treatments that address mechanisms of therapeutic resistance in cancer, with ORIC-944 being an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) [11]